Gains of segments containing putative drug targets are also among the GBM-specific CNAs, including the methyltransferases-encoding METTL2B (7q32.1) and METTL2A (17q23.2), and the serine/threonine kinase-encoding TLK2 (17q23.2) [8, 57]. This evidence concerns the gene MARK2 and glioblastoma.